{"id":"NCT02076399","sponsor":"Rigel Pharmaceuticals","briefTitle":"A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-14","primaryCompletion":"2016-04-21","completion":"2016-04-21","firstPosted":"2014-03-03","resultsPosted":"2019-01-11","lastUpdate":"2019-02-12"},"enrollment":76,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"Fostamatinib disodium","otherNames":["R935788","R788","Fostamatinib"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fostamatinib Disodium","type":"EXPERIMENTAL"},{"label":"Placebo","type":"OTHER"}],"summary":"The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).","primaryOutcome":{"measure":"Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24)","timeFrame":"From Week 14 to Week 24","effectByArm":[{"arm":"Fostamatinib Recipient","deltaMin":9,"sd":null},{"arm":"Placebo Recipient","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0261"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":52,"countries":["United States","Australia","Canada","Denmark","Hungary","Italy","Netherlands","United Kingdom"]},"refs":{"pmids":["33995988"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":51},"commonTop":["Diarrhoea","Nausea","Hypertension","Headache","Dizziness"]}}